Hans-Peter Halbritter

Hans Peter Halbritter looks back on more than twenty-seven years of experience as a commercial biopharma executive in the area of severe chronic and rare diseases, including distinct experience in immunology, hemophilia, rare hematology, neurology, and critical care. Hans Peter held several national and regional leadership roles as managing director at Baxalta and as director of various business units at Baxter, Baxalta, and Shire.

He gained a wealth of commercial experience in his role in heading the EMEA launch of world-leading, rare hematology therapies and through a variety of national and international leadership roles. Hans Peter directed large, diversified teams, medium-sized marketing and sales organizations, as well as small and powerful specialized teams in the field of rare diseases and specialty care.

Over the last few years, he has put his leadership focus on organizational change processes to increase commercial efficiency and effectiveness in the framework of corporate spin-off and integration initiatives. Transformational change leadership and the development of purpose-driven, high-performing teams are prominent key topics on his agenda as commercial manager, leader, and consultant.

Over several years, Hans Peter acted as a board member of the Plasma Protein Therapeutics Association, PPTA, in Germany. Most recently, Hans Peter founded Trisalta GmbH - a Biopharma Consulting firm working with clients in the specialty care and rare disease space.

Hans Peter Halbritter holds a master’s degree in biology from the Ludwig-Maximilians-University in Munich, Germany.